WO2012102562A3 - 신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물 - Google Patents

신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물 Download PDF

Info

Publication number
WO2012102562A3
WO2012102562A3 PCT/KR2012/000619 KR2012000619W WO2012102562A3 WO 2012102562 A3 WO2012102562 A3 WO 2012102562A3 KR 2012000619 W KR2012000619 W KR 2012000619W WO 2012102562 A3 WO2012102562 A3 WO 2012102562A3
Authority
WO
WIPO (PCT)
Prior art keywords
dementia
treatment
composition containing
active ingredient
methylhonokiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/000619
Other languages
English (en)
French (fr)
Other versions
WO2012102562A2 (ko
Inventor
한상배
정재경
곽영신
서승용
이기호
송석길
홍진태
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Bioland Co Ltd
Original Assignee
Bioland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioland Ltd filed Critical Bioland Ltd
Publication of WO2012102562A2 publication Critical patent/WO2012102562A2/ko
Publication of WO2012102562A3 publication Critical patent/WO2012102562A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/54—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 메틸호노키올 유도체를 유효성분으로 포함하는 치매의 치료, 예방 또는 개선용 조성물을 제공한다. 본 발명의 메틸호노키올 유도체는 베타-아밀로이드(β-amyloid) 응집 억제 효과, 베타-세크리타제(β-secretase) 활성 억제 효과, 베타-아밀로이드(β-amyloid)에 의한 신경세포의 사멸 억제 효과를 나타낸다. 따라서, 본 발명의 메틸호노키올 유도체는 베타 아밀로이드에 의해 유발되는 치매 질환의 치료제 및 기능성 식품의 활성성분으로 개발될 수 있다.
PCT/KR2012/000619 2011-01-26 2012-01-26 신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물 Ceased WO2012102562A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110007831A KR101305524B1 (ko) 2011-01-26 2011-01-26 신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물
KR10-2011-0007831 2011-01-26

Publications (2)

Publication Number Publication Date
WO2012102562A2 WO2012102562A2 (ko) 2012-08-02
WO2012102562A3 true WO2012102562A3 (ko) 2013-03-07

Family

ID=46581296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000619 Ceased WO2012102562A2 (ko) 2011-01-26 2012-01-26 신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101305524B1 (ko)
WO (1) WO2012102562A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
WO2025116596A1 (ko) * 2023-11-29 2025-06-05 가천대학교 산학협력단 신규 화합물 및 이를 포함하는 안질환 예방 또는 치료용 조성물
CN118666734A (zh) * 2024-05-27 2024-09-20 上海植瑞新成医药科技有限公司 一种和厚朴酚衍生物及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition
KR20020087724A (ko) * 2001-05-16 2002-11-23 김호철 신경보호작용을 갖는 후박 추출물 및 이를 함유하는약학적 제제
KR20080075403A (ko) * 2007-02-12 2008-08-18 바이오스펙트럼 주식회사 바이페닐 다이올 유도체 및 이를 유효성분으로 포함하는조성물
WO2008153958A2 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
WO2009058300A1 (en) * 2007-10-30 2009-05-07 Arena Pharmaceuticals, Inc. Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto
KR100926466B1 (ko) * 2008-09-25 2009-11-13 주식회사 바이오랜드 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 약제 조성물
KR100932962B1 (ko) * 2008-09-25 2009-12-21 주식회사 바이오랜드 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 개선 또는 예방용 기능성 식품조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5053548A (en) * 1989-02-08 1991-10-01 Otsuka Pharmaceutical Company, Ltd. Biphenyl derivative composition for nerve cell degeneration repairing or protective agent and process for preparing a phenyl derivative contained in the composition
KR20020087724A (ko) * 2001-05-16 2002-11-23 김호철 신경보호작용을 갖는 후박 추출물 및 이를 함유하는약학적 제제
KR20080075403A (ko) * 2007-02-12 2008-08-18 바이오스펙트럼 주식회사 바이페닐 다이올 유도체 및 이를 유효성분으로 포함하는조성물
WO2008153958A2 (en) * 2007-06-08 2008-12-18 Arena Pharmaceuticals, Inc. Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto
WO2009058300A1 (en) * 2007-10-30 2009-05-07 Arena Pharmaceuticals, Inc. Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto
KR100926466B1 (ko) * 2008-09-25 2009-11-13 주식회사 바이오랜드 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 치료 또는 예방용 약제 조성물
KR100932962B1 (ko) * 2008-09-25 2009-12-21 주식회사 바이오랜드 4-ｏ-메틸호노키올을 함유하는 아밀로이드 관련 질환의 개선 또는 예방용 기능성 식품조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEE, YONG KYUNG ET AL.: "Protective effect of the ethanol extract of Magnolia officinalis and 4-0-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity.", J. NAT. MED., vol. 63, 2009, pages 274 - 282 *
PARK, SO-YOUNG.: "Potential Therapeutic Agents against Alzheimer's Disease from Natural Sources.", ARCH. PHARM. RES., vol. 33, no. 10, 2010, pages 1589 - 1609 *
REDDY, K. YALLA ET AL.: "Review On Effect of Natural Memory Enhancing Drugs On Dementia.", INTERNATIONAL JOURNAL OF PHYTOPHARMACOLOGY, vol. 1, no. 1, 2010, pages 1 - 7 *

Also Published As

Publication number Publication date
WO2012102562A2 (ko) 2012-08-02
KR101305524B1 (ko) 2013-09-06
KR20120086531A (ko) 2012-08-03

Similar Documents

Publication Publication Date Title
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2011090270A3 (ko) 오스모틴을 포함하는 신경질환의 예방 및 치료용 조성물
WO2016073774A3 (en) Immunoregulatory agents
WO2015101958A3 (en) Inhibitors of glutaminase
WO2014031928A3 (en) Heterocyclic modulators of hif activity for treatment of disease
GEP20207172B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2013134085A8 (en) Inhibitors of beta-secretase
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2014031933A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EP3038474A4 (en) Nutraceutical combination for prevention and treatment of type 2 diabetes
EP3102220A4 (en) Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders
WO2014031936A3 (en) Heterocyclic modulators of hif activity for treatment of disease
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
EP3661502A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
PH12016501527B1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
WO2012102560A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체 및 이를 유효성분으로 포함하는 염증질환 치료용 조성물
HK1213175A1 (zh) Tspo介导的疾病和/或病症的治疗和/或预防
WO2016178510A3 (ko) 진세노사이드 Ｆ1 또는 Ｒｇ3를 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
WO2012102562A3 (ko) 신규한 4-ｏ-메틸호노키올 유도체를 유효성분으로 포함하는 치매 치료용 조성물
EP3203998A4 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739950

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12739950

Country of ref document: EP

Kind code of ref document: A2